Tribune News Service
New Delhi, September 15
The ICMR mentioned on Tuesday early proof from one among its randomised managed trials on the efficacy of convalescent plasma has proven that the remedy didn’t cut back mortality nor did it forestall development from reasonable to extreme illness.
ICMR chief Balram Bhargava mentioned the examine performed on 464 sufferers throughout 39 hospitals was nonetheless below peer assessment and full publication of the outcomes was awaited.
“Once we get the final publication we will take a decision on whether to continue advising use of plasma therapy as an off label therapy for COVID management in India,” Bhargava mentioned indicating prospects of assessment of the earlier steering by ICMR and consequent nervousness amongst a bunch of COVID sufferers to safe convalescent plasma.
Several states have gone to the extent of establishing plasma banks with the efficacy of the remedy nonetheless unproven.